Compare EVTL & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVTL | CTNM |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 607.7M | 507.0M |
| IPO Year | N/A | 2024 |
| Metric | EVTL | CTNM |
|---|---|---|
| Price | $3.92 | $13.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $13.20 | ★ $19.80 |
| AVG Volume (30 Days) | ★ 669.5K | 201.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.76 | $3.35 |
| 52 Week High | $7.60 | $16.33 |
| Indicator | EVTL | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 43.17 |
| Support Level | $3.71 | $10.39 |
| Resistance Level | $4.70 | $16.17 |
| Average True Range (ATR) | 0.21 | 1.17 |
| MACD | 0.01 | -0.26 |
| Stochastic Oscillator | 32.59 | 15.58 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero operating emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.